ADC Therapeutics SA

General Information


We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted ADCs for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation PBD technology to which we have proprietary rights for our targets. We are leveraging our R&D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline.

Employees: 125
Founded: 2011
Contact Information
Address Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland
Phone Number +41 21 653 02 00
Web Address
View Prospectus: ADC Therapeutics SA
Financial Information
Market Cap $1794.7mil
Revenues $2.9 mil (last 12 months)
Net Income $-111.1 mil (last 12 months)
IPO Profile
Symbol ADCT
Exchange NYSE
Shares (millions): 8.2
Price range $23.00 - $26.00
Est. $ Volume $200.0 mil
Manager / Joint Managers Morgan Stanley/ BofA Merrill Lynch/ Cowen
CO-Managers -
Expected To Trade: 10/3/2019
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change